In particular, they studied the outcome of COVID-19 patients coincidentally treated with FDA-approved therapeutics directed against two of the proviral dependency factors (whose inhibition significantly decreased virus production): the above-mentioned prostaglandin E synthase type 2 (PGES-2, encoded by PTGES2) and sigma non-opioid receptor 1 (sigma-1, encoded by SIGMAR1). This evidence concerns the gene SIGMAR1 and COVID-19.